Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR

Xiao-Dong Yu1, Rui Yang2, Chang-Jun Leng3

  • 1Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou 318000, China.

Insights

The tumor suppressor MIG6 regulates epidermal growth factor receptor (EGFR) in lung cancer. Computational and experimental studies show that modifying a key MIG6 peptide segment enhances its binding affinity to EGFR, offering new therapeutic strategies.

Area of Science:

  • Molecular biology
  • Biochemistry
  • Structural biology

Background:

  • Epidermal growth factor receptor (EGFR) is crucial in lung cancer progression and metastasis.
  • Tumor suppressor MIG6 negatively regulates EGFR activity by disrupting its dimerization.
  • MIG6 utilizes two distinct segments to interact with the EGFR kinase domain.

Purpose of the Study:

  • To computationally model and analyze the interaction between the EGFR kinase domain and MIG6 segment 2 peptide.
  • To investigate the binding affinity of modified MIG6 peptides to the EGFR kinase domain.
  • To explore potential therapeutic strategies targeting EGFR in lung cancer.

Main Methods:

  • Computational modeling and analysis of intermolecular interactions.
  • Truncation of MIG6 segment 2 to create a peptide fragment.
  • Synthesis and purification of peptide derivatives (phosphorylated, dephosphorylated, double-point mutant).
  • Fluorescence anisotropy titration to determine binding affinities to recombinant human EGFR kinase domain.

Main Results:

  • MIG6 segment 2 peptide adopts a two-stranded β-sheet structure, with β-strand 2 interacting with the EGFR activation loop.
  • A C-terminal region within β-strand 2 is critical for peptide binding.
  • Phosphorylation and specific mutations significantly enhance the binding affinity of the truncated MIG6 peptide to EGFR kinase domain.
  • Experimental results align with computational predictions, showing improved binding with phosphorylation and mutation.

Conclusions:

  • The study elucidates the structural basis of MIG6-EGFR interaction at the peptide level.
  • Phosphorylation and mutation of MIG6-derived peptides can modulate their affinity for EGFR.
  • These findings provide a foundation for developing novel EGFR-targeted therapies for lung cancer.